Results 41 to 50 of about 5,401 (177)

Vismodegib for the treatment of radiation-induced basal cell carcinoma – a case report and brief literature study

, 2019
Vismodegib is playing an increasing role in the treatment of locally advanced or metastatic basal cell carcinoma (BCC) that is not a candidate for surgery or radiotherapy, and also in radiation-induced BCC.
Davide Baldaccini, Andrea Antonuzzo, Fabiola Paiar, Concetta Laliscia   +3 more
core   +1 more source

Enhanced and sustained cutaneous delivery of vismodegib by ablative fractional laser and microemulsion formulation

, 2020
Oral administration of vismodegib for basal cell carcinoma treatment is limited by significant class-specific systemic side-effects. We investigated the approach of combining ablative fractional laser (AFL)-assisted drug delivery with an extended-release
Andresen, T.L., Olesen, Uffe Høgh, Hendel, Kristoffer Kjærgaard, Yeung, K., Yeung, Kelvin, Clergeaud, Gael, Hendel, K.K., Andresen, Thomas Lars, Haedersdal, Merete, Lerche, Catharina Margrethe, Lerche, C.M., Olesen, U.H.   +11 more
core   +1 more source

Vismodegib for periocular basal cell carcinoma: an international multicentre case series

, 2020
Introduction Vismodegib (Erivedge, Genentech) is a first-in-class inhibitor of the hedgehog (Hh) pathway, which is licensed for use in locally advanced basal cell carcinoma (BCC) and metastatic BCC.
Clarke, L., Cranstoun, M., Althaus, M., D. Morris, H. Oliphant, A. Haridas, P. Norris, S. N. Rajak, Sullivan, T. J., J. Laybourne, M. Cranstoun, Morris, D., L. Clarke, Norris, P., Chan, K., T. J. Sullivan, K. Chan, Rajak, S. N., Oliphant, H., Laybourne, J., M. R. Edmunds, M. Althaus, Haridas, A., Edmunds, M. R.   +23 more
core   +2 more sources

Inhibition of Hedgehog signaling ameliorates foam cell formation by promoting autophagy in early atherosclerosis

Cell Death and Disease, 2023
Macrophages are the origin of most foam cells in the early stage of atherosclerotic plaques. However, the mechanism involved in the formation of macrophage-derived foam cell formation remains unclear. Here, we revealed that the hedgehog (Hh) signaling is
Yuting Zhang, Weijuan Xin, Xiaozhi Hu, Hanqi Wang, Xiaomiao Ye, Caili Xu, Yanyang Nan, Zhengyu Wu, Dianwen Ju, Jiajun Fan   +9 more
doaj   +1 more source

Transformation of facial basal cell carcinoma to squamous cell carcinoma following vismodegib

Otolaryngology Case Reports, 2021
Objective(s): Vismodegib, a unique hedgehog pathway inhibitor, has been demonstrated to be effective in the treatment of non-operable and metastatic basal cell carcinoma (BCC).
Dustin A. Silverman, Michael M. Li, Thomas E. Olencki, Nolan B. Seim, Theodoros N. Teknos, Stephen Y. Kang   +5 more
doaj   +1 more source

24 | Management of advanced basal cell carcinoma with hedgehog inhibitors: a real-world prospective comparative study

Dermatology Reports
Background: Hedgehog Pathway Inhibitors (HHIs) should be offered to patients with advanced BCC as a first line treatment. Two systemic HHIs are currently available: sonidegib and vismodegib.
Italian Melanoma Intergroup
doaj   +1 more source

Tailored Toxicity-Driven Administration of Vismodegib in Patients With Multiple or Locally Advanced Basal Cell Carcinoma: A Pilot Analysis

Frontiers in Oncology, 2020
In this pilot study, we describe our experience with vismodegib in the treatment of basal cell carcinoma (BCC) and evaluate the feasibility of a tailored toxicity-driven administration of vismodegib in patients with multiple or locally advanced BCC.
Maria Chiara Tronconi, Alessandra Solferino, Laura Giordano, Riccardo Borroni, Riccardo Borroni, Luca Mancini, Armando Santoro, Armando Santoro   +7 more
doaj   +1 more source

Comparative Response of Canine and Human Osteosarcoma Tumour Cell Lines to Molecularly Targeted Anticancer Agents at Clinically Relevant Exposures With Analysis of Genomic Biomarkers

Veterinary and Comparative Oncology, EarlyView.
ABSTRACT Osteosarcoma (OSA) is a primary bone tumour occurring in children but is also prevalent in large breed dogs. Canine OSA (cOSA) has long been viewed as analogous to human OSA (hOSA) with cOSA serving as a surrogate for development of therapeutic approaches to treat the rarer human form.
Daniel L. Gustafson, Kala A. Early, Maritza A. Morales, Klaudia A. Poplawski, Sunetra Das, Dawn L. Duval   +5 more
wiley   +1 more source

Vismodegib in locally advanced basal cell carcinoma in Slovenia

, 2022
Background: Vismodegib is a first-in-class inhibitor of the hedgehog pathway for treatment of locally advanced basal cell carcinoma (laBCC) and metastatic BCC. Objectives: The purpose of this study is to report outcomes of patients with laBCC, with basal
Maša Sever, Ocvirk, Janja, Janja Ocvirk, Mesti, Tanja, Sever, Maša, Tanja Mesti   +5 more
core   +1 more source

Phase I and phase II sonidegib and vismodegib clinical trials for the treatment of paediatric and adult MB patients: a systemic review and meta-analysis

Acta Neuropathologica Communications, 2019
Background Medulloblastoma (MB) is the most common malignant brain tumour in children but also rarely occur in adults. Sonic Hedgehog (SHH) driven MB is associated with aberrant activation of the SHH signalling pathway.
Yuchen Li, Qingkun Song, Bryan W. Day
doaj   +1 more source